Erenumab in chronic migraine
Patient-reported outcomes in a randomized double-blind study

Richard B. Lipton, MD, Stewart J. Tepper, MD, Uwe Reuter, MD, et al.

Cite as: Neurology® 2019;92:e2250-e2260. doi:10.1212/WNL.0000000000007452

Correspondence
Dr. Lipton
Richard.Lipton@einstein.yu.edu

Study objective and summary result
This study examined the effects of erenumab on health-related quality of life (HRQoL), headache burdens, and disability in patients with chronic migraine (CM), and it found that erenumab provides improvements in all 3 outcomes in patients with CM.

Classification of evidence
Class II.

What is known and what this paper adds
A randomized clinical trial showed that erenumab reduces monthly migraine days in patients with CM. This study further analyzed the trial’s data to show that erenumab yields improvements in other outcomes.

Participants and setting
This trial included 667 adults with CM (83% female; mean age, 42 ± 11 years), which was defined as experiencing ≥15 headache days per month, including ≥8 migraine days. This trial was conducted through 69 sites in the US, Canada, and Europe, between March 2014 and April 2016.

Design, size, and duration
This double-blind phase 2 trial used a randomization scheme involving stratification by region and medication overuse to assign participants to groups receiving placebo treatment (n = 286) or erenumab at doses of 70-mg/mo (n = 191) or 140-mg/mo (n = 190). At baseline and follow-up timepoints, this trial assessed HRQoL, headache burdens, and migraine-related disability with the Migraine-Specific Quality-of-Life Questionnaire (MSQ), the Headache Impact Test (HIT-6), and the Migraine Disability Assessment Test (MIDAS), respectively.

Primary outcome measures
The primary outcomes were from-baseline changes in MSQ, HIT-6, and MIDAS scores at 3 months.

Main results and the role of chance
Greater-than-placebo improvements were observed for all 3 primary outcomes at both erenumab doses at 3 months.

Table

<table>
<thead>
<tr>
<th>Outcome</th>
<th>OR (95% CI) for outcome relative to placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>MSQ-RFR score increase ≥5</td>
<td>1.9 (1.1–3.3) 2.8 (1.6–4.9)</td>
</tr>
<tr>
<td>HIT-6 total score decrease ≥5</td>
<td>2.3 (1.5–3.4) 2.3 (1.5–3.4)</td>
</tr>
<tr>
<td>MIDAS score consistent with severe disability</td>
<td>0.4 (0.3–0.7) 0.4 (0.2–0.6)</td>
</tr>
</tbody>
</table>

Abbreviations: CI = confidence interval; MSQ-RFR = role function-restrictive MSQ domain; OR = odds ratio. Score changes are relative to baseline.

Harms
Few participants experienced serious adverse events.

Bias, confounding, and other reasons for caution
This trial had a short duration.

Generalizability to other populations
This study’s recruitment of participants in high-income countries may limit the generalizability of the results to residents of middle- and low-income countries.

Study funding/potential competing interests
This study was funded by Amgen. Some authors report receiving consulting and teaching fees, honoraria, committee appointments, and funding from the NIH and various healthcare companies, including Amgen; having stock and stock options in various healthcare companies, including Amgen; receiving publishing royalties; and receiving employment from Amgen and the American Headache Society. Go to Neurology.org/N for full disclosures.

Trial registration number
NCT02066415 on ClinicalTrials.gov.

A draft of the short-form article was written by M. Dalefield, a writer with Editage, a division of Cactus Communications. The authors of the full-length article and the journal editors edited and approved the final version.
Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study
Richard B. Lipton, Stewart J. Tepper, Uwe Reuter, et al.

Neurology 2019;92:e2250-e2260 Published Online before print April 17, 2019
DOI 10.1212/WNL.0000000000007452

This information is current as of April 17, 2019

<table>
<thead>
<tr>
<th>Updated Information &amp; Services</th>
<th>including high resolution figures, can be found at: <a href="http://n.neurology.org/content/92/19/e2250.full">http://n.neurology.org/content/92/19/e2250.full</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>References</td>
<td>This article cites 24 articles, 3 of which you can access for free at: <a href="http://n.neurology.org/content/92/19/e2250.full#ref-list-1">http://n.neurology.org/content/92/19/e2250.full#ref-list-1</a></td>
</tr>
<tr>
<td>Subspecialty Collections</td>
<td>This article, along with others on similar topics, appears in the following collection(s):</td>
</tr>
<tr>
<td></td>
<td>All Clinical trials <a href="http://n.neurology.org/cgi/collection/all_clinical_trials">http://n.neurology.org/cgi/collection/all_clinical_trials</a></td>
</tr>
<tr>
<td></td>
<td>Class II <a href="http://n.neurology.org/cgi/collection/class_ii">http://n.neurology.org/cgi/collection/class_ii</a></td>
</tr>
<tr>
<td></td>
<td>Migraine <a href="http://n.neurology.org/cgi/collection/migraine">http://n.neurology.org/cgi/collection/migraine</a></td>
</tr>
<tr>
<td></td>
<td>Quality of life <a href="http://n.neurology.org/cgi/collection/quality_of_life">http://n.neurology.org/cgi/collection/quality_of_life</a></td>
</tr>
<tr>
<td>Permissions &amp; Licensing</td>
<td>Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="http://www.neurology.org/about/about_the_journal#permissions">http://www.neurology.org/about/about_the_journal#permissions</a></td>
</tr>
<tr>
<td>Reprints</td>
<td>Information about ordering reprints can be found online: <a href="http://n.neurology.org/subscribers/advertise">http://n.neurology.org/subscribers/advertise</a></td>
</tr>
</tbody>
</table>